Effect of NAC on Sleep Apnea

This study is not yet open for participant recruitment.

Verified by Assaf-Harofeh Medical Center, May 2007

First Received: January 1, 2008 Last Updated: January 11, 2008 History of Changes

Sponsored by:	Assaf-Harofeh Medical Center
Information provided by:	Assaf-Harofeh Medical Center
ClinicalTrials.gov Identifier:	NCT00592618

Purpose

Sleep studies in ESRD patients have identified increased prevalence of Sleep Apnea. Based on current knowledge, treatment aimed at reducing oxidative stress might improve Sleep Apnea in HD patients. The aim of our study is to investigate the effect of N-acetylsysteine on Sleep Apnea in HD patients.

Condition	Intervention
ESRD Sleep Apnea	Drug: Oral N-Acetylcysteine 1200 mg x 2/day for 4 weeks

MedlinePlus related topics: Sleep Apnea

Drug Information available for: Acetylcysteine

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Open Label, Active Control, Single Group Assignment, Safety Study

Further study details as provided by Assaf-Harofeh Medical Center:

Show Detailed Description

Eligibility

Ages Eligible for Study:	20 Years to 85 Years
Genders Eligible for Study:	Both

Criteria

Inclusion Criteria:

The study will include 20 patients with ESRD, treated with chronic hemodialysis in Assaf Harofeh Medical Center and suffering from sleep disturbances, such as frequent arousals, snoring, daytime sleepiness.

Exclusion Criteria:

Patients will be excluded from the study if they are:

Recently started treated with chronic dialysis: less than 3 months.
Survived recent major illness, requiring hospitalisation in the last 3 months.
Patients with acute renal failure
Currently treated with antioxidants ( NAC, vitamin E ets.)
Current use of sleep pills

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00592618

Contacts

Contact: Leonid S Feldman, MD

+972-8-9779383

leonidf@asaf.health.gov.il

Locations

Israel
Nephrology Division, Assaf Harofeh Medical Center
Zerifin, Israel, 70300

Sponsors and Collaborators

Assaf-Harofeh Medical Center

Investigators

Principal Investigator:

Leonid S Feldman, MD

Assaf Harofeh MC

More Information

No publications provided

Study ID Numbers:	346147SLEEP
Study First Received:	January 1, 2008
Last Updated:	January 11, 2008
ClinicalTrials.gov Identifier:	NCT00592618 History of Changes
Health Authority:	Israel: Ministry of Health

Keywords provided by Assaf-Harofeh Medical Center:

ESRD
Hemodialysis
Sleep Apnea
Hemodialysis

Study placed in the following topic categories:

Sleep Apnea Syndromes
Antioxidants
Apnea
Respiration Disorders
Sleep Disorders
Dyssomnias
Antiviral Agents

Sleep Disorders, Intrinsic
Signs and Symptoms
Respiratory Tract Diseases
Expectorants
Signs and Symptoms, Respiratory
Acetylcysteine
N-monoacetylcystine

Additional relevant MeSH terms:

Anti-Infective Agents
Respiratory System Agents
Sleep Apnea Syndromes
Antioxidants
Molecular Mechanisms of Pharmacological Action
Apnea
Physiological Effects of Drugs
Respiration Disorders
Nervous System Diseases
Dyssomnias
Sleep Disorders
Protective Agents

Antiviral Agents
Pharmacologic Actions
Sleep Disorders, Intrinsic
Signs and Symptoms
Respiratory Tract Diseases
Therapeutic Uses
Expectorants
Free Radical Scavengers
Signs and Symptoms, Respiratory
Acetylcysteine
N-monoacetylcystine
Antidotes

ClinicalTrials.gov processed this record on May 07, 2009